Topical Lidocaine: Predictors of Response in Peripheral Nerve Injury

Overview

The primary purpose is to study the predictive value of preserved nociceptors and large afferent fibers and dynamic mechanical allodynia on the effect of lidocaine patch. The primary outcome measure is the predictive role for these three measures for obtaining a response to lidocaine. A responder is defined as a person with at least a 2-point pain reduction to lidocaine (change in median pain intensity (measured on a 10 point numeric rating scale) of pain from the baseline week to the last week of lidocaine treatment). Secondary effect variable will be efficacy of lidocaine on pain reduction (baseline week versus last week of each treatment) and pain relief (complete, good, moderate, slight, none, or worse) for spontaneous and evoked pain, and effect on ongoing pain, brush evoked allodynia, cold and warm allodynia, and pinprick hyperalgesia evaluated on each visit.

Full Title of Study: “Evaluation of Predictors of Response for the Efficacy of Topical Lidocaine Patch (Versatis) on Chronic Neuropathic Pain After Peripheral Nerve Injury”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2011

Interventions

  • Drug: Topical lidocaine patch
    • Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.

Clinical Trial Outcome Measures

Primary Measures

  • Change in pain intensity (measured daily on a 10 point NRS)of spontaneous pain from baseline week to last week of treatment
    • Time Frame: 4 or 12 weeks
    • The primary purpose is to study the predictive value of preserved nociceptors and large afferent fibers and dynamic mechanical allodynia on the effect of lidocaine patch. The primary outcome measure is the predictive role for these three measures for obtaining a response to lidocaine. A responder is defined as a person with at least a 2-point pain reduction to lidocaine (change in median pain intensity (measured on a 10 point NRS) of pain from the baseline week to the last week.

Secondary Measures

  • Pain relief (complete, good, moderate, slight, none, or worse) for spontaneous and evoked pain
    • Time Frame: 4 or 12 weeks
  • Effect on ongoing pain, brush-evoked allodynia, cold and warm allodynia, and pinprick hyperalgesia
    • Time Frame: 4 or 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • patients aged 18 or more with neuropathic pain after a peripheral nerve injury with a pain intensity of at least 4 on a 0-10 point numeric rating scale. Exclusion Criteria:

  • pregnancy or lactation, – allergy to lidocaine, – alcohol abuse, – psychiatric disorders, – skin diseases in the area where the patches are to be applied, – treatment with class I antiarrhythmic agents, – any treatment within the past one month or concomitantly with Na2+-channel blockers (e.g., mexiletine, phenytoine, propafenone), – any topical treatment with capsaicin within the last three months before entering the study, or any other topical treatment in the area of neuropathic pain, – concomitant therapy with TENS or acupuncture.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Danish Pain Research Center
  • Collaborator
    • Grünenthal Denmark ApS
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nanna B. Finnerup, MD, DMSc., Principal Investigator, Danish Pain Research Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.